Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 3, 2007, Pages 560-564

  Stocker, Hartmut ^a,b   Herzmann, Christian ^a   Breske, Antje ^a   Kruse, Guido ^a   Berger, Marcel ^a,b   Schulbin, Hubert ^a,b   Hill, Andrew ^c   Steinmüller, Jutta ^c   Becker, Mark ^c   Arastéh, Keikawus ^a,b   Kurowski, Michael ^a  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

AIDS; Cytochromes; Double boosting; Drug interactions; HIV

Indexed keywords

ANTIVIRUS AGENT; DRUG METABOLITE; HYDROXY T BUTYLAMIDE; NELFINAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; HYDROXY T BUTYLAMIDENELFINAVIR; HYDROXY-T-BUTYLAMIDENELFINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; OPEN STUDY; PARALLEL DESIGN; SIDE EFFECT; STEADY STATE; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; RITONAVIR; SAQUINAVIR;

EID: 34248189706     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl516     Document Type: Article

References (10)

1. Hammer SM, Vaida F, Bennett KK et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 2002; 288: 169-80.
2. Casado JL, Moreno S, Hertogs K et al. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 2002; 16: 47-52.
3. Squires K, Currier J, Clark R et al. Final 48-week results of a phase II, randomized study of the safety, efficacy, and pharmacokinetics of BID vs TID nelfinavir and saquinavir in combination with lamivudine and stavudine in HIV-positive women (women first trial). In: Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 2001. Abstract 330. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
4. Merry C, Barry M, Mulcahy F et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients. In: Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 1998. Abstract 352. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
5. Kempf DJ, Marsh KC, Kumar G et al. Pharmacokinetic enhancement of inhibitors of ft human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60.
6. Kurowski M, Kaeser B, Sawyer A et al. Low-dose ritonavir moderstely enhances nelfinavir exposure. Clin Pharmacol Ther 2002; 72: 123-32.
7. von Moltke LL, Greenblatt DJ, Grassi JM et al. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11.
8. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32: 1462-7.
9. Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing etavirenz and/ or nelfinavir: An Adult Aids Clinical Trials Group study. J Infect Dis 2005; 192: 1931-42.
10. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4.